SCHEMBL24913835

SCHEMBL24913835

CN(c1cccc2c1CN(C(=O)OC(C)(C)C)CC2)C1CCOC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.43
ESR2 Q92731 1/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
UCHL1 P09936 1/20 0.40
PRMT5 O14744 4/20 0.39
WDR77 Q9BQA1 4/20 0.39
MAPK1 P28482 1/20 0.39
TIPARP Q7Z3E1 1/20 0.39
TMEM97 Q5BJF2 2/20 0.39
SIGMAR1 Q99720 2/20 0.39
KDM1A O60341 1/20 0.38
GPR119 Q8TDV5 1/20 0.37
ABHD6 Q9BV23 1/20 0.37
USP30 Q70CQ3 2/20 0.37
NAMPT P43490 1/20 0.37
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30789184 1.00 NR1H2 (0.43) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL29168638 0.86 TIPARP (0.40) PRMT5WDR77TIPARPTMEM97SIGMAR1
SCHEMBL30156843 0.83 NR1H2 (0.46) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL24914007 0.83 NR1H2 (0.46) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL31014035 0.78 KDM1A (0.47) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL24914056 0.78 ESR2 (0.43) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL24913992 0.78 ESR2 (0.43) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL30789218 0.78 ESR2 (0.43) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL24913832 0.78 ESR2 (0.43) NR1H2ESR2DDB1CRBNUCHL1
SCHEMBL31062499 0.76 NR1H2 (0.40) NR1H2ESR2DDB1CRBNUCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240293392-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2024-09-05 US disclosed
CN-117693507-A Inhibitor compounds 奈奥芬莱有限公司 2024-03-12 CN disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 WO disclosed
WO-2023002165-A1 INHIBITOR COMPOUNDS Neophore Limited (GB) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240293392-A1 INHIBITOR COMPOUNDS MSH2, PMS2, MSH6 NR1H2 2027/4885ESR2 568/4885DDB1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.